Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13

Rhea-AI Summary

Vaxart, Inc. (NASDAQ: VXRT) will host a conference call on May 13, 2024, to provide a business update and report financial results for the first quarter ending March 31, 2024. Investors can access the conference call online or by phone, and submit questions in advance. A replay will be available on the company's website.

News Market Reaction – VXRT

-3.63%

-3.63% Session move

In the trading session that priced this news, VXRT declined 3.63%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference call to begin at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2024 after the market close on Monday, May 13, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.

The conference call can be accessed using the following information:

Webcast: Click here
Date: Monday, May 13, 2024 – 4:30 p.m. ET
Domestic: (877) 407-0832
International: (201) 689-8433
Conference ID: 13745591

Investors may submit written questions in advance of the conference call to ir@vaxart.com.

A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts
Vaxart Media Relations: Mark Herr Vaxart, Inc. mherr@vaxart.com (203) 517-8957		Investor Relations: Andrew Blazier FINN Partners IR@vaxart.com (646) 871-8486

        

FAQ

When will Vaxart host the conference call for the first quarter 2024 business update and financial results?

Vaxart will host the conference call on May 13, 2024.

What will be discussed during the conference call?

Vaxart will provide a business update and report financial results for the first quarter ending March 31, 2024.

How can investors access the conference call?

Investors can access the conference call online or by phone, using the provided Webcast link and phone numbers.

Can investors submit questions in advance of the conference call?

Yes, investors can submit written questions in advance of the conference call to ir@vaxart.com.

Where can investors find a replay of the webcast after the conference call?

A replay of the webcast will be available on the Company's website at www.vaxart.com.